服务平台拥有丰富的技术服务经验，一流的仪器设备，先进的检测手段和严格的质量控制体系，力求为全球药物研发机构提供优质高效的技术服务
背景介绍 The enzyme PDE-4 is found mainly in inflammatory cells, and Roflumilast acts as a selective, long-acting inhibitor of PDE-4. It has anti-inflammatory effects and is under development as an orally administered drug for the treatment of inflammatory conditions of the lungs such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). In vitro studies show that roflumilast inhibits the production of inflammatory mediators in a variety of human immune cells, suggesting a role for reducing COPD-related inflammation. Roflumilast is also found to decrease glucose levels in patients with newly diagnosed type-2 diabetes since diabetes is an important comorbidity associated with COPD. 产品介绍 Roflumilast is an orally active, selective inhibitor of phophodiesterase-4 (PDE-4) with IC50 value of 0.11 nM . Roflumilast displays anti-inflammatory and immunomodulatory in vitro.
询价背景介绍 The enzyme PDE-4 is found mainly in inflammatory cells, and Roflumilast acts as a selective, long-acting inhibitor of PDE-4. It has anti-inflammatory effects and is under development as an orally administered drug for the treatment of inflammatory conditions of the lungs such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). In vitro studies show that roflumilast inhibits the production of inflammatory mediators in a variety of human immune cells, suggesting a role for reducing COPD-related inflammation. Roflumilast is also found to decrease glucose levels in patients with newly diagnosed type-2 diabetes since diabetes is an important comorbidity associated with COPD. 产品介绍 Roflumilast is an orally active, selective inhibitor of phophodiesterase-4 (PDE-4) with IC50 value of 0.11 nM . Roflumilast displays anti-inflammatory and immunomodulatory in vitro.
询价背景介绍 The enzyme PDE-4 is found mainly in inflammatory cells, and Roflumilast acts as a selective, long-acting inhibitor of PDE-4. It has anti-inflammatory effects and is under development as an orally administered drug for the treatment of inflammatory conditions of the lungs such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). In vitro studies show that roflumilast inhibits the production of inflammatory mediators in a variety of human immune cells, suggesting a role for reducing COPD-related inflammation. Roflumilast is also found to decrease glucose levels in patients with newly diagnosed type-2 diabetes since diabetes is an important comorbidity associated with COPD. 产品介绍 Roflumilast is an orally active, selective inhibitor of phophodiesterase-4 (PDE-4) with IC50 value of 0.11 nM . Roflumilast displays anti-inflammatory and immunomodulatory in vitro.
询价产品介绍 Rocilinostat, also known as ACY-1215, is a selective HDAC6 inhibitor with IC50 of 5 nM. It is over 10-fold more selective for HDAC6 than HDAC1, 2, 3 (class I HDACs) with slight activity against HDAC8, and minimal activity against HDAC4, 5, 7, 9, 11, SIRT1, and SIRT2.
询价产品介绍 Rocilinostat, also known as ACY-1215, is a selective HDAC6 inhibitor with IC50 of 5 nM. It is over 10-fold more selective for HDAC6 than HDAC1, 2, 3 (class I HDACs) with slight activity against HDAC8, and minimal activity against HDAC4, 5, 7, 9, 11, SIRT1, and SIRT2.
询价产品介绍 Rocilinostat, also known as ACY-1215, is a selective HDAC6 inhibitor with IC50 of 5 nM. It is over 10-fold more selective for HDAC6 than HDAC1, 2, 3 (class I HDACs) with slight activity against HDAC8, and minimal activity against HDAC4, 5, 7, 9, 11, SIRT1, and SIRT2.
询价背景介绍 RGFP966 is a slow-on/slow-off, competitive tight-binding HDAC inhibitor. RGFP966 treatment on two CTCL cell lines for 24 hours prior to western blot analysis resulted in increased acetylation at H3K9/K14, H3K27, and H4K5, but not H3K56ac. RGFP966 decreases cell growth in CTCL (cutaneous T cell lymphoma) cell lines due to increased apoptosis that is associated with DNA damage and impaired S phase progression. 产品介绍 RGFP966 is specific for HDAC3, with an IC50 of 0.08 µM and no effective inhibition of any other HDAC at concentrations up to 15 µM.
询价背景介绍 RGFP966 is a slow-on/slow-off, competitive tight-binding HDAC inhibitor. RGFP966 treatment on two CTCL cell lines for 24 hours prior to western blot analysis resulted in increased acetylation at H3K9/K14, H3K27, and H4K5, but not H3K56ac. RGFP966 decreases cell growth in CTCL (cutaneous T cell lymphoma) cell lines due to increased apoptosis that is associated with DNA damage and impaired S phase progression. 产品介绍 RGFP966 is specific for HDAC3, with an IC50 of 0.08 µM and no effective inhibition of any other HDAC at concentrations up to 15 µM.
询价背景介绍 RGFP966 is a slow-on/slow-off, competitive tight-binding HDAC inhibitor. RGFP966 treatment on two CTCL cell lines for 24 hours prior to western blot analysis resulted in increased acetylation at H3K9/K14, H3K27, and H4K5, but not H3K56ac. RGFP966 decreases cell growth in CTCL (cutaneous T cell lymphoma) cell lines due to increased apoptosis that is associated with DNA damage and impaired S phase progression. 产品介绍 RGFP966 is specific for HDAC3, with an IC50 of 0.08 µM and no effective inhibition of any other HDAC at concentrations up to 15 µM.
询价
